{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:15:10Z","timestamp":1773864910473,"version":"3.50.1"},"reference-count":50,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHAMC"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Immune thrombocytopenia is an immune condition where antibodies are produced\nagainst platelets. Eltrombopag is a thrombopoietin receptor agonist that stimulates and promotes\nplatelet production approved for treating thrombocytopenia in patients with chronic immune thrombocytopenia,\nwhere other treatments such as corticosteroids, splenectomy or immunoglobulins are\ninadequate. The aim of this meta-analysis was to evaluate the efficacy and safety of the eltrombopag\nin adults and children with immune thrombocytopenia. We included 7 studies with a total of\n765 patients (606 adults and 159 children). We evaluated the number of patients that achieved a\npost-treatment platelet count equal or above 50x10&lt;sup&gt;9&lt;\/sup&gt;\/L (primary result-target) without the need of\nrescue treatment for at least 4 weeks. Our data showed that patients who received eltrombopag\nwere almost 4 times more probable in achieving the primary target when compared to patients who\nreceived placebo (RR 3.84, 95% CI 2.39 to 6.14; I&lt;sup&gt;2&lt;\/sup&gt; = 46%). The number of patients needed rescue\ntreatment and the number of bleeding incidents were reduced in the group that received eltrombopag\nwhen compared to those who received placebo (RR 0.40, 95% CI 0.25 to 0.62; I&lt;sup&gt;2&lt;\/sup&gt; = 40%) (RR\n0.74, 95% CI 0.62 to 0.89; I&lt;sup&gt;2&lt;\/sup&gt; = 68%). The total number of side effects did not statistically differ between\nthe two groups (RR 0.99, 95% CI 0.90 to 1.08; I&lt;sup&gt;2&lt;\/sup&gt; = 14%). Our findings were similar to previously\npublished studies and confirm that eltrombopag is safe and efficient in immune thrombocytopenia.\nHowever, more clinical trials are needed in order to enhance our findings.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871525718666200910161540","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T11:52:36Z","timestamp":1599825156000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-9196","authenticated-orcid":true,"given":"Savvas","family":"Kolanis","sequence":"first","affiliation":[{"name":"2nd Department of Pediatrics, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-8744","authenticated-orcid":true,"given":"Eleni","family":"Vasileiou","sequence":"additional","affiliation":[{"name":"2nd Department of Pediatrics, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-2970","authenticated-orcid":true,"given":"Emmanuel","family":"Hatzipantelis","sequence":"additional","affiliation":[{"name":"2nd Department of Pediatrics, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-4348","authenticated-orcid":true,"given":"Marina","family":"Economou","sequence":"additional","affiliation":[{"name":"1st Department of Paediatrics, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-2605","authenticated-orcid":true,"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"2nd Department of Pediatrics, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jpeds.2014.05.030","volume":"165","author":"Buchanan G.R.","year":"2014","unstructured":"Buchanan G.R.; Immune thrombocytopenia during childhood: New approaches to classification and management. J Pediatr 2014,165(3),437-439","journal-title":"J Pediatr"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1517\/14656566.2015.1085512","volume":"16","author":"Merli P.","year":"2015","unstructured":"Merli P.; Strocchio L.; Vinti L.; Palumbo G.; Locatelli F.; Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opin Pharmacother 2015,16(14),2243-2256","journal-title":"Expert Opin Pharmacother"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.12888","volume":"165","author":"Mah\u00e9vas M.","year":"2014","unstructured":"Mah\u00e9vas M.; Fain O.; Ebbo M.; Roudot-Thoraval F.; Limal N.; Khellaf M.; Schleinitz N.; Bierling P.; Languille L.; Godeau B.; Michel M.; The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 2014,165(6),865-869","journal-title":"Br J Haematol"},{"key":"ref=4","first-page":"3","volume":"67","author":"Koloni\u0107 S.O.","year":"2013","unstructured":"Koloni\u0107 S.O.; Patekar M.B.; Milunovi\u0107 V.; [Diagnostic approach and treatment of immune thrombocytopenia in adults]. Acta Med Croatica 2013,67(1),3-11 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24279250","journal-title":"Acta Med Croatica"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2165\/11207390-000000000-00000","volume":"71","author":"Garnock-Jones K.P.","year":"2011","unstructured":"Garnock-Jones K.P.; Eltrombopag: A review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs 2011,71(10),1333-1353","journal-title":"Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/08880010050122816","volume":"17","author":"Zeller B.","unstructured":"Zeller B.; Helgestad J.; Hellebostad M.; Immune thrombocytopenic purpura in childhood in Norway: A prospective, population based registration. Pediatr Hematol Oncol [Online: ] [Accessed: February 17, 2019].,17(7),551-558","journal-title":"Pediatr Hematol Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jpeds.2014.03.060","volume":"165","author":"Ramaswamy K.","year":"2014","unstructured":"Ramaswamy K.; Hsieh L.; Leven E.; Thompson M.V.; Nugent D.; Bussel J.B.; Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr 2014,165(3),600-5.e4","journal-title":"J Pediatr"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/adc.72.2.125","volume":"72","author":"Reid M.M.","year":"1995","unstructured":"Reid M.M.; Chronic idiopathic thrombocytopenic purpura: Incidence, treatment, and outcome. Arch Dis Child 1995,72(2),125-128","journal-title":"Arch Dis Child"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","volume":"386","author":"Grainger J.D.","year":"2015","unstructured":"Grainger J.D.; Locatelli F.; Chotsampancharoen T.; Donyush E.; Pongtanakul B.; Komvilaisak P.; Sosothikul D.; Drelichman G.; Sirachainan N.; Holzhauer S.; Lebedev V.; Lemons R.; Pospisilova D.; Ramenghi U.; Bussel J.B.; Bakshi K.K.; Iyengar M.; Chan G.W.; Chagin K.D.; Theodore D.; Marcello L.M.; Bailey C.K.; Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): A randomised, multicentre, placebo-controlled trial. Lancet 2015,386(10004),1649-1658","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"Bussel J.B.","year":"2015","unstructured":"Bussel J.B.; de Miguel P.G.; Despotovic J.M.; Grainger J.D.; Sevilla J.; Blanchette V.S.; Krishnamurti L.; Connor P.; David M.; Boayue K.B.; Matthews D.C.; Lambert M.P.; Marcello L.M.; Iyengar M.; Chan G.W.; Chagin K.D.; Theodore D.; Bailey C.K.; Bakshi K.K.; Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): A randomised, multicentre, placebo-controlled study. Lancet Haematol 2015,2(8),e315-e325","journal-title":"Lancet Haematol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","volume":"10","author":"Tomiyama Y.","year":"2012","unstructured":"Tomiyama Y.; Miyakawa Y.; Okamoto S.; Katsutani S.; Kimura A.; Okoshi Y.; Ninomiya H.; Kosugi H.; Nomura S.; Ozaki K.; Ikeda Y.; Hattori T.; Katsura K.; Kanakura Y.; A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012,10(5),799-806","journal-title":"J Thromb Haemost"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa073275","volume":"357","author":"Bussel J.B.","year":"2007","unstructured":"Bussel J.B.; Cheng G.; Saleh M.N.; Psaila B.; Kovaleva L.; Meddeb B.; Kloczko J.; Hassani H.; Mayer B.; Stone N.L.; Arning M.; Provan D.; Jenkins J.M.; Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007,357(22),2237-2247","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"Cheng G.","year":"2011","unstructured":"Cheng G.; Saleh M.N.; Marcher C.; Vasey S.; Mayer B.; Aivado M.; Arning M.; Stone N.L.; Bussel J.B.; Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011,377(9763),393-402","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","volume":"98","author":"Kuter D.J.","year":"2013","unstructured":"Kuter D.J.; The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013,98(1),10-23","journal-title":"Int J Hematol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bjh.12781","volume":"165","author":"Kuter D.J.","year":"2014","unstructured":"Kuter D.J.; Milestones in understanding platelet production: A historical overview. Br J Haematol 2014,165(2),248-258","journal-title":"Br J Haematol"},{"key":"ref=16","author":"Justiz Vaillant A.A.","unstructured":"Justiz Vaillant A.A.; Gupta N.;  Thrombocytopenic Purpura Immune StatPearls Publishing; 2018. [Online: ], [Accessed February 18, 2019].","journal-title":"Thrombocytopenic Purpura Immune"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1651-2227.1997.tb08876.x","volume":"86","author":"Hedman A.","year":"1997","unstructured":"Hedman A.; Henter J.I.; Hedlund I.; Elinder G.; Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden. Acta Paediatr 1997,86(2),226-227 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9055900","journal-title":"Acta Paediatr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1185\/03007995.2011.644849","volume":"28","author":"Fogarty P.F.","year":"2012","unstructured":"Fogarty P.F.; Tarantino M.D.; Brainsky A.; Signorovitch J.; Grotzinger K.M.; Selective validation of the WHO bleeding scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012,28(1),79-87","journal-title":"Curr Med Res Opin"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"Neunert C.","year":"2011","unstructured":"Neunert C.; Lim W.; Crowther M.; Cohen A.; Solberg L.; Crowther M.A.; The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood American Society of Hematology2011,117(16),4190-4207","journal-title":"Blood"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ccr3.1086","volume":"5","author":"Bergmann S.","year":"2017","unstructured":"Bergmann S.; Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions. Clin Case Rep 2017,5(10),1660-1663","journal-title":"Clin Case Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jpeds.2009.10.015","volume":"156","author":"Mantadakis E.","year":"2010","unstructured":"Mantadakis E.; Farmaki E.; Buchanan G.R.; Thrombocytopenic purpura after measles-mumps-rubella vaccination: A systematic review of the literature and guidance for management. J Pediatr 2010,156(4),623-628","journal-title":"J Pediatr"},{"key":"ref=22","first-page":"1333","volume":"373","author":"Boyers D.","year":"2011","unstructured":"Boyers D.; Jia X.; Jenkinson D.;  Lancet 2011,373,1333-1353","journal-title":"Lancet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41598-017-19099-8","volume":"8","author":"Zhang J.","year":"2018","unstructured":"Zhang J.; Liang Y.; Ai Y.; Li X.; Xie J.; Li Y.; Zheng W.; He R.; Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis. Sci Rep 2018,8(1),576","journal-title":"Sci Rep"},{"key":"ref=24","first-page":"1171","volume":"23","author":"Dmytrijuk A.","year":"2009","unstructured":"Dmytrijuk A.; Robie-Suh K.; Rieves D.; Pazdur R.; Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) [Online: ]2009,23(13),1171-1177","journal-title":"Oncology (Williston Park)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(09)60377-9","volume":"373","author":"Panzer S.","year":"2009","unstructured":"Panzer S.; Pabinger I.; Eltrombopag in chronic idiopathic thrombocytopenic purpura. Lancet 2009,373(9664),607-608","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjh.14380","volume":"176","author":"Yang R.","year":"2017","unstructured":"Yang R.; Li J.; Jin J.; Huang M.; Yu Z.; Xu X.; Zhang X.; Hou M.; Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol 2017,176(1),101-110","journal-title":"Br J Haematol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2165\/00003495-200969050-00005","volume":"69","author":"Garnock-Jones K.P.","year":"2009","unstructured":"Garnock-Jones K.P.; Keam S.J.; Eltrombopag. Drugs 2009,69(5),567-576","journal-title":"Drugs"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","volume":"373","author":"Bussel J.B.","year":"2009","unstructured":"Bussel J.B.; Provan D.; Shamsi T.; Cheng G.; Psaila B.; Kovaleva L.; Salama A.; Jenkins J.M.; Roychowdhury D.; Mayer B.; Stone N.; Arning M.; Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 2009,373(9664),641-648","journal-title":"Lancet"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40265-016-0581-4","volume":"76","author":"Burness C.B.","year":"2016","unstructured":"Burness C.B.; Keating G.M.; Garnock-Jones K.P.; Eltrombopag: A review in paediatric chronic immune thrombocytopenia. Drugs 2016,76(8),869-878","journal-title":"Drugs"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12185-014-1533-y","volume":"99","author":"Tripathi A.K.","year":"2014","unstructured":"Tripathi A.K.; Shukla A.; Mishra S.; Yadav Y.S.; Yadav D.K.; Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients. Int J Hematol 2014,99(4),413-417","journal-title":"Int J Hematol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00277-010-0953-x","volume":"89","author":"K\u00fchne T.","year":"2010","unstructured":"K\u00fchne T.; Imbach P.; Eltrombopag: An update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Ann Hematol 2010,89(S1)(Suppl. 1),67-74","journal-title":"Ann Hematol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00277-016-2896-3","volume":"96","author":"Gonz\u00e1lez K.J.","year":"2017","unstructured":"Gonz\u00e1lez K.J.; Zuluaga S.O.; DaRos C.V.; Rodr\u00edguez P.P.; Mart\u00ed A.C.; Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): Experience in our center. Ann Hematol 2017,96(3),507-508","journal-title":"Ann Hematol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fped.2015.00070","volume":"3","author":"Garzon A.M.","year":"2015","unstructured":"Garzon A.M.; Mitchell W.B.; Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Front Pediatr 2015,3,70","journal-title":"Front Pediatr"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/pbc.26003","volume":"63","author":"Neunert C.","year":"2016","unstructured":"Neunert C.; Despotovic J.; Haley K.; Lambert M.P.; Nottage K.; Shimano K.; Bennett C.; Klaassen R.; Stine K.; Thompson A.; Pastore Y.; Brown T.; Forbes P.W.; Grace R.F.; Thrombopoietin receptor agonist use in children: Data from the pediatric ITP Consortium of North America ICON2 study. Pediatr Blood Cancer Pediatric ITP Consortium of North America (ICON)2016,63(8),1407-1413","journal-title":"Pediatr Blood Cancer"},{"key":"ref=35","first-page":"60","volume":"12","author":"Osman M.E.","year":"2012","unstructured":"Osman M.E.; Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist. Sudan J Paediatr [Online: ]2012,12(2),60-64","journal-title":"Sudan J Paediatr"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e26657","DOI":"10.1002\/pbc.26657","volume":"64","author":"Ehrlich L.A.","year":"2017","unstructured":"Ehrlich L.A.; Kwitkowski V.E.; Reaman G.; Ko C.W.; Nie L.; Pazdur R.; Farrell A.T.; U.S. Food and drug administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia. Pediatr Blood Cancer 2017,64(12),e26657","journal-title":"Pediatr Blood Cancer"},{"key":"ref=37","unstructured":"Revolade 75 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (eMC). [Online: ], [Accessed: February 23, 2019]."},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12185-015-1787-z","volume":"101","author":"Miano M.","year":"2015","unstructured":"Miano M.; Dufour C.; The diagnosis and treatment of aplastic anemia: a review. Int J Hematol 2015,101(6),527-535","journal-title":"Int J Hematol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"Killick S.B.","year":"2016","unstructured":"Killick S.B.; Bown N.; Cavenagh J.; Dokal I.; Foukaneli T.; Hill A.; Hillmen P.; Ireland R.; Kulasekararaj A.; Mufti G.; Snowden J.A.; Samarasinghe S.; Wood A.; Marsh J.C.; British Society for standards in haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016,172(2),187-207","journal-title":"Br J Haematol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/11591550-000000000-00000","volume":"30","author":"Boyers D.","year":"2012","unstructured":"Boyers D.; Jia X.; Jenkinson D.; Mowatt G.; Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: A NICE single technology appraisal. Pharmacoeconomics 2012,30(6),483-495","journal-title":"Pharmacoeconomics"},{"key":"ref=41","unstructured":"PRISMA-P (Preferred reporting items for systematic review and meta-analysis protocols) 2015 Checklist: Recommended items to address in a systematic review protocol* section and topic item no checklist item. [Online: ] [Accessed February 7, 2019]."},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MBC.0b013e32835fac99","volume":"24","author":"Tarantino M.D.","year":"2013","unstructured":"Tarantino M.D.; Fogarty P.; Mayer B.; Vasey S.Y.; Brainsky A.; Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis 2013,24(3),284-296","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"CD008235","DOI":"10.1002\/14651858.CD008235.pub2","volume":"7","author":"Zeng Y.","year":"2011","unstructured":"Zeng Y.; Duan X.; Xu J.; Ni X.;  Cochrane Database Syst Rev 2011,7,CD008235","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.clinthera.2011.10.004","volume":"33","author":"Zhang Y.","year":"2011","unstructured":"Zhang Y.; Kolesar J.M.; Eltrombopag: An oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Clin Ther 2011,33(11),1560-1576","journal-title":"Clin Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/1076029616663849","volume":"23","author":"Elgebaly A.S.","year":"2017","unstructured":"Elgebaly A.S.; Ashal G.E.; Elfil M.; Menshawy A.; Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: Meta-Analysis of Randomized Controlled Trials. Clin Appl Thromb Hemost 2017,23(8),928-937","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref=46","unstructured":"Meta-analysis - Eltrombopag - Full Text View - ClinicalTrials.gov. [Online:  ], [Accessed: August 16, 2018]."},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1542\/peds.2012-3807","volume":"132","author":"Favier R.","year":"2013","unstructured":"Favier R.; Feriel J.; Favier M.; Denoyelle F.; Martignetti J.A.; First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics 2013,132(3),e793-e795","journal-title":"Pediatrics"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","volume":"126","author":"Gerrits A.J.","year":"2015","unstructured":"Gerrits A.J.; Leven E.A.; Frelinger A.L.; Brigstocke S.L.; Berny-Lang M.A.; Mitchell W.B.; Revel-Vilk S.; Tamary H.; Carmichael S.L.; Barnard M.R.; Michelson A.D.; Bussel J.B.; Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia. Blood 2015,126(11),1367-1378","journal-title":"Blood"},{"key":"ref=49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012055","author":"Desborough M.","year":"2016","unstructured":"Desborough M.; Hadjinicolaou A.V.; Chaimani A.;  Cochrane Database of Systematic Reviews 2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"CD012035","DOI":"10.1002\/14651858.CD012035.pub2","volume":"11","author":"Zhang X.","year":"2017","unstructured":"Zhang X.; Chuai Y.; Nie W.; Wang A.; Dai G.; Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev 2017,11,CD012035","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cardiovascular &amp; Hematological Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/185842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.eurekaselect.com\/185842\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/eurekaselect.com\/article\/download\/185842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T14:51:49Z","timestamp":1641999109000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/185842\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871525718666200910161540","relation":{},"ISSN":["1871-5257"],"issn-type":[{"value":"1871-5257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}